The safety analyses included all patients who received cemiplimab (n = 60), and the primary efficacy analyses included 50 of these patients with PD-L1 expression in ≥50% of tumor cells confirmed by central laboratory PD-L1 testing. This evidence concerns the gene CD274 and neoplasm.